ePRO eCOA eSource DDC eConsent Infectious Disease

Will Coronavirus Force New Wave of Technology Adoption in Clinical Trials?

Technology for decentralized trials, bring your own device (BYOD) ePRO, and direct data capture (DDC) have been in place for several years, but the implementation of these hybrid approaches has stagnated. While cleaner data, reduced cost, and patient engagement are all benefits of hybrid study implementations, unfortunately, perhaps the biggest accelerator to their wider adoption will be the COVID-19 pandemic. With cancellations increasing daily, and people avoiding gathering places (especially doctor’s offices), the practicality of hybrid trials stands out and leaves the industry to question – will the Coronavirus force a new wave of technology adoption in clinical trials?

Our CEO, Ed Seguine, offers his opinion to ACRP: https://acrpnet.org/2020/03/24/will-coronavirus-force-new-wave-of-technology-adoption-in-clinical-trials/

Topics: ePRO, eCOA, eSource DDC, eConsent, Infectious Disease

Subscribe to Email Updates